Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Barco, Davide Voci, Ulrike Held, Tim Sebastian, Roland Bingisser, Giuseppe Colucci, Daniel Duerschmied, Andrè Frenk, B. Gerber, Andrea Götschi,

The Lancet Haematology · 2022 · 59 citations · 11 references

DOIFull text

Open access

Concepts

References

11